Peptides for Gut Health: Evidence-Based Options for Digestive Support

Key Takeaways

• Compounds covered: BPC-157, KPV (Lys-Pro-Val), larazotide acetate
• Goal area: Gastrointestinal mucosal repair, intestinal barrier integrity, and gut inflammation
• Evidence range: Ranges from completed Phase 3 RCT in humans (larazotide, celiac disease; program discontinued after failed primary endpoint) to preclinical animal studies (BPC-157) to in vitro cell models (KPV)
• Regulatory range: Larazotide is investigational (Phase 3 did not meet primary endpoint; not approved); BPC-157 and KPV are not on the FDA 503A bulks list and have no legal compounding pathway as of publication
• Key biomarkers for gut health: hs-CRP, comprehensive metabolic panel (ALT, AST, eGFR), CBC, calprotectin (where clinically indicated)
• As of April 2026: In April 2026, FDA removed BPC-157 and KPV from its interim Category 2 list without placing either on Category 1. Neither is eligible for 503A compounding. No gut-targeted peptide discussed here is FDA-approved for clinical use.
• Bottom line: Larazotide has the most extensive human RCT dataset in this cluster; BPC-157 has the most extensive preclinical dataset; KPV has mechanistic specificity that makes it relevant for IBD research.

Understanding Gut Health: The Biology

The gastrointestinal tract is not simply a digestive tube. It is also the largest immune organ in the body, the site of the enteric nervous system (often called the "second brain"), and the interface between the external environment and systemic circulation. The intestinal mucosal barrier — a single layer of epithelial cells joined by tight junction proteins — is what maintains this interface. When tight junction integrity is compromised, microbial products, dietary antigens, and inflammatory signals can translocate into systemic circulation; this has been proposed as a mechanism for immune activation that extends beyond the gut.

Fasano's foundational 2011 review in Physiological Reviews proposed zonulin as a regulator of intestinal barrier function — characterizing dysregulated zonulin as a proposed contributor to inflammation, autoimmunity, and systemic disease. His 2020 update in F1000Research reviewed zonulin-mediated gut permeability in the pathogenesis of chronic inflammatory diseases, cementing intestinal barrier disruption as a clinically relevant target.

Three distinct mechanisms are relevant to gut-targeted peptides. First, cytoprotection and mucosal healing: the restoration of the intestinal epithelial lining after injury from NSAIDs, ischemia, infection, or surgical intervention. Second, tight junction reinforcement: direct modulation of the proteins (claudins, occludins, ZO-1) that seal intercellular gaps in the epithelium. Third, anti-inflammatory signaling: suppression of cytokine cascades, particularly NF-κB-mediated pathways, within intestinal epithelial and immune cells. Each of the compounds in this article targets one or more of these mechanisms — and they are mechanistically distinct enough that understanding which one does what is essential context for any clinical conversation.

The gut-brain axis adds a fourth layer of relevance: bidirectional signaling between the enteric nervous system and the CNS via vagal, endocrine, and immune pathways means that gut barrier disruption is not localized. Jozwiak and colleagues, in a comprehensive 2025 review in Pharmaceuticals, reviewed BPC-157's preclinical multifunctionality across organ systems, including proposed effects on gut-brain crosstalk.

Peptides Studied for Gut Health: A Quick Comparison

The following peptides have published evidence relevant to gut health. They are listed by strength of clinical evidence, from most-studied in humans to least.

• Compound: Larazotide acetate
  Mechanism for gut health: Has been shown in preclinical and human studies to promote tight junction assembly by acting on the zonulin pathway, which is associated with reduced paracellular gap formation and reduced intestinal permeability
  Evidence: Phase 3 RCT in celiac disease (Kelly et al., 2013; Leffler et al., 2012); Phase 2 data in non-celiac applications. Phase 3 program did not meet primary endpoint in 2022.
  FDA status: Not FDA-approved. Completed a Phase 3 RCT in celiac disease (2022); the sponsor did not subsequently pursue FDA approval for the celiac indication.
  SP availability: Not currently available through Superpower
  Route: Oral
• Compound: BPC-157
  Mechanism for gut health: Cytoprotective and mucosal-regenerative peptide with VEGFR2 activation, nitric oxide system involvement, and intestinal barrier stabilization
  Evidence: Extensive preclinical animal studies; no published Phase 2 or Phase 3 RCT results for BPC-157 in IBD are available in indexed pharmaceutical literature
  FDA status: Not FDA-approved. In April 2026, FDA removed BPC-157 from its interim Category 2 list without placing it on Category 1. Not eligible for 503A compounding.
  SP availability: Not offered by Superpower; no legal US compounding or prescribing pathway available.
  Route: Subcutaneous injection or oral (animal model research context only; no approved human administration route).
• Compound: KPV (Lys-Pro-Val)
  Mechanism for gut health: Tripeptide fragment of alpha-MSH that enters intestinal epithelial and immune cells via PepT1 transporter, suppressing NF-κB and MAP kinase inflammatory cascades
  Evidence: In vitro cell models; preclinical murine colitis models; delivery system research; no human clinical trial
  FDA status: Research-only; not approved for human use; not available by prescription in the US
  SP availability: Not offered by Superpower; no legal US compounding or prescribing pathway available.
  Route: Oral (nanoparticle delivery in research); topical in mucosal applications

Compounds listed as research-only have not completed the clinical trial process required for FDA approval. They are not legal to prescribe or sell for human use in the US. Their inclusion here is for educational context only.

Peptides Studied for Gut Health: Individual Profiles

Each compound targets a distinct mechanism and has a different evidence footprint. Evaluating them separately — rather than as interchangeable "gut peptides" — is what makes a clinical discussion of any of them productive.

BPC-157: cytoprotection and mucosal repair

BPC-157 (body protection compound 157) is a 15-amino-acid synthetic peptide derived from a sequence found in human gastric juice. It is referred to in the literature as a stable gastric pentadecapeptide and was isolated by Sikiric and colleagues at the University of Zagreb, who have produced the majority of published research on this compound over more than three decades.

The foundational overview by Sikiric and colleagues in Current Pharmaceutical Design in 2011 described BPC-157's cytoprotective and anti-ulcer properties in preclinical models and established it as a novel gastrointestinal research compound. A 2018 review in Current Pharmaceutical Design by Sikiric and colleagues described BPC-157's cytoprotective activity in animal models, including vascular recruitment and GI mucosal recovery through vascular endothelial growth factor receptor 2 (VEGFR2). Hsieh and colleagues, writing in the Journal of Molecular Medicine in 2017, demonstrated the VEGFR2 activation mechanism directly — providing molecular-level evidence for the angiogenic and vascular recruitment activity underlying gut repair in preclinical models. Park and colleagues, in a 2020 paper in Current Pharmaceutical Design, reported BPC-157 effects on NSAID-induced cytotoxicity in animal models, with stabilized intestinal permeability and enhanced cytoprotection — directly relevant to drug-induced gut damage, a common clinical concern. [Animal study]

BPC-157's documented range in preclinical models extends to structural GI recovery. Sikiric and colleagues showed in a 2009 paper in Digestive Diseases and Sciences that BPC-157 improved villus height and crypt depth and restored weight in a short bowel syndrome animal model. A 2013 study in the Journal of Physiology and Pharmacology by Sikiric and colleagues reported reduced lesion burden in colitis model and improved colon anastomosis in a cysteamine-induced rodent model. A 2023 paper in Pharmaceuticals by Sikiric and colleagues argued that BPC-157 may support brain-gut axis function in preclinical models — extending its relevance to gut-brain crosstalk.

The nitric oxide system is central to BPC-157's proposed mechanism. Sikiric and colleagues, in a Journal of Pharmacological Sciences paper in 2008, documented colocutaneous fistula recovery in animal models with NO-system involvement, describing the signaling pathway associated with GI recovery. A 2017 paper in Current Pharmaceutical Design by Sikiric and colleagues reviewed BPC-157's role in counteracting stress-induced GI damage in preclinical models, positioning it as a stress-responsive compound for gut protection in the research literature.

BPC-157 is not FDA-approved for any indication. In April 2026, FDA removed BPC-157 from its interim Category 2 list of substances under review without placing it on the Category 1 (permitted) list. As a result, BPC-157 is not on the FDA 503A bulks list and is not eligible for 503A compounding in the United States as of publication. BPC-157 is also not on the 503B clinical need list and is not a component of any FDA-approved drug; no 503B outsourcing pathway exists. No US 503A or 503B compounding pathway is available for BPC-157. It is not available through Superpower or any licensed prescriber.

KPV: targeted intestinal anti-inflammatory signaling

KPV (Lys-Pro-Val) is a tripeptide corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). It represents the pharmacophore responsible for most of alpha-MSH's anti-inflammatory activity, as Getting and colleagues established in a 2003 paper in the Journal of Pharmacology and Experimental Therapeutics dissecting the anti-inflammatory effects of alpha-MSH fragments.

KPV's gut-specific mechanism has been well characterized in preclinical models. Dalmasso and colleagues, publishing in Gastroenterology in 2008, demonstrated that KPV enters epithelial cells via PepT1, dampening NF-κB and MAP kinase signaling — providing direct cellular evidence for how KPV suppresses gut inflammation in vitro. A companion paper by Kannengiesser and colleagues in Inflammatory Bowel Diseases in 2008 showed KPV effects independent of melanocortin receptors in intestinal epithelial cells — a mechanism distinct from those of current IBD therapies. [In vitro and murine colitis models; no human clinical trial]

Laroui and colleagues advanced the delivery science considerably. A 2016 paper in Cellular and Molecular Gastroenterology and Hepatology by Viennois and colleagues demonstrated PepT1 role in colitis-associated cancer in murine models — suggesting that KPV's anti-inflammatory effects in the colon may extend to cancer risk reduction in preclinical IBD models. A 2017 paper in Molecular Therapy by Xiao and colleagues showed that HA-functionalized nanoparticle delivery reduced colitis severity in murine models — demonstrating that targeted delivery can address KPV's peptide stability challenges. A 2010 paper by Laroui and colleagues in Gastroenterology provided early proof-of-concept for polysaccharide-hydrogel nanoparticle delivery to colon.

KPV is a research compound. No human clinical trial has been published. In April 2026, FDA removed KPV from its interim Category 2 list without placing it on Category 1. KPV is not on the FDA 503A bulks list and is not eligible for 503A or 503B compounding. It is not available through licensed prescribers for any indication, and it is not available through Superpower.

Larazotide acetate: tight junction restoration in clinical trials

Larazotide acetate (AT-1001) is a synthetic octapeptide derived from zonula occludens toxin that has been studied for its effects on the tight junction pathway and paracellular permeability. Among the compounds discussed in this article, it has the most extensive human RCT dataset — the only one with completed human randomized controlled trial data in celiac disease.

The mechanistic foundation was established by Gopalakrishnan and colleagues, publishing in Peptides in 2012, who reported that larazotide acetate promotes tight junction assembly in epithelial cells by acting on ZO-1 and preventing assembly of paracellular channels. A comprehensive pharmacological review by Slifer and colleagues in the American Journal of Physiology - Gastrointestinal and Liver Physiology in 2021 covered larazotide mechanism and clinical development. [Phase 3 RCT in celiac disease; primary endpoint not met]

The anchor clinical study is a randomized double-blind trial by Kelly and colleagues published in Alimentary Pharmacology and Therapeutics in 2013, in which larazotide acetate was associated with reduced intestinal permeability during gluten challenge in a controlled human study. Leffler and colleagues published a parallel randomized placebo-controlled study in the American Journal of Gastroenterology in 2012 reporting effects during celiac gluten challenge. A 2021 paper by Slifer and colleagues in PLoS One extended larazotide in acute intestinal injury scenarios — reporting tight junction repair in ischemia-injured porcine jejunum. A 2025 paper (ahead of print) continues to document larazotide's protective role on intestinal mucosal barrier in preclinical settings, reflecting ongoing active investigation.

Larazotide is not FDA-approved. Its Phase 3 celiac disease program (9 Meters Biopharma's CeDLara trial) did not meet its primary endpoint in 2022, and the sponsor did not subsequently pursue FDA approval for the celiac indication. It remains an investigational compound. It is not available through US compounding pharmacies for general clinical use and is not available through Superpower.

Regulatory Status at a Glance

As of April 2026, the peptides discussed in this article carry different regulatory statuses.

• BPC-157: Not FDA-approved for any indication. In April 2026, FDA removed BPC-157 from its interim Category 2 list without placing it on Category 1. BPC-157 is not on the FDA 503A bulks list and is not eligible for 503A compounding in the United States as of publication. BPC-157 is also not on the 503B clinical need list and is not a component of any FDA-approved drug; no 503B outsourcing pathway exists. No US 503A or 503B compounding pathway is available for BPC-157.
• KPV (Lys-Pro-Val): Not on the FDA 503A bulks list and not eligible for 503A compounding. In April 2026, FDA removed KPV from its interim Category 2 list without placing it on Category 1. No US 503A or 503B compounding pathway exists for KPV. Inclusion in this article is for educational context only.
• Larazotide acetate: Not FDA-approved. Completed a Phase 3 RCT in celiac disease (2022); the Phase 3 program did not meet its primary endpoint and the sponsor did not subsequently pursue FDA approval for the celiac indication. Larazotide remains an investigational compound; it is not available through US compounding pharmacies for general clinical use.
• Important: None of the three peptides discussed in this article has a legal compounding or prescribing pathway for general clinical use in the US. None is available through Superpower.

Compounds listed as research-only are not legal to prescribe, compound, or sell for human use in the US. Their presence in this article is for educational context only.

Considerations When Comparing Peptides for Gut Health

A provider evaluating gut-targeted peptides will distinguish between the structural repair question, the inflammatory suppression question, and the barrier integrity question — because different compounds address each differently.

Direct comparison between these compounds is not straightforward — they have been studied in different populations, at different doses, and using different endpoints. Inferring relative effectiveness from separate trials is methodologically unreliable.

Your specific GI presentation: Active mucosal injury from NSAID use, surgical anastomosis, or ischemia — BPC-157's preclinical profile is most directly relevant here. Celiac disease with documented intestinal permeability — larazotide has the only human RCT evidence. Colitis or IBD with inflammatory driver — KPV's NF-κB suppression mechanism is relevant, though no human data exists.

Evidence level comfort: Larazotide has the most rigorous human evidence of any compound here — Phase 3 RCTs in a defined population. BPC-157 has extensive preclinical data across multiple models. KPV has mechanistically specific cell-level data but no human trials. This gradient matters when discussing evidence with a provider.

Route and practical considerations: Larazotide is oral. BPC-157 is typically injectable in clinical contexts, though the research team that developed it has studied oral administration for GI-specific effects. KPV delivery is an active research area; current formulations are not available outside research settings.

Regulatory status: BPC-157 and KPV are not on the FDA 503A bulks list and are not legally compoundable in the US as of publication. Larazotide is investigational and not available through compounding. Access to any of these compounds outside a clinical trial is not available through a legal US pathway as of publication.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety data for the compounds in this article range from limited human trial data to preclinical-only. No blanket safety statement applies.

Larazotide has the most human safety data: the Phase 3 RCTs documented its tolerability profile in patients with celiac disease. BPC-157 has an extensive preclinical safety record in published animal studies; systematic human safety data for BPC-157 is not publicly available in the form of adequate and well-controlled clinical trials. KPV has cell-model and murine data, but no human safety trials have been conducted. For any injectable compound, liver function and kidney function baselines are standard safety assessments.

Broad contraindications relevant to gut health peptide therapy include:

• Active malignancy involving the gastrointestinal tract — cytoprotective and angiogenic compounds require provider risk assessment in oncology contexts
• Pregnancy or breastfeeding — no reproductive safety data exists for any investigational peptide in this list
• Known hypersensitivity to any component of a compounded or investigational formulation
• Severe immunosuppression — anti-inflammatory compounds including KPV carry theoretical immunosuppression considerations in significantly immunocompromised individuals
• Gray-market injectable sources — products sold outside licensed pharmacy channels carry contamination and dosing risks that cannot be verified

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides for Gut Health

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing the expected physiological changes — or whether those changes are beneficial.

• hs-CRP: High-sensitivity C-reactive protein quantifies systemic inflammatory burden. Why it matters for gut health: gut barrier disruption drives systemic low-grade inflammation, and hs-CRP is the most accessible marker of that systemic signal. A baseline value establishes whether inflammatory burden is elevated before any peptide is introduced, and provides a reference for tracking changes.
• Liver enzymes (ALT, AST) via liver health panel: Standard safety baseline for any injectable compound. The liver processes peptides and is the first organ affected by gut-derived endotoxin translocation — relevant if barrier disruption is driving hepatic inflammation. ALT is a sensitive marker of hepatocellular stress.
• eGFR and creatinine: Kidney function baseline for any injectable compound. Renal clearance affects peptide pharmacokinetics and establishes safety context before any injectable therapy. Testing eGFR provides the key renal function reference.
• CBC: Complete blood count provides general hematologic context. Elevated eosinophils may suggest allergic or parasitic gut inflammation; anemia patterns are relevant in IBD contexts where malabsorption is a driver.
• Calprotectin (stool): Fecal calprotectin is a sensitive marker of intestinal inflammation — far more specific to GI inflammation than serum CRP. Where clinical IBD is under investigation, stool calprotectin establishes the mucosal inflammation baseline. This is a provider-ordered test.
• Glucose and HbA1c: Metabolic baseline relevant to any compound interacting with intestinal signaling pathways. GLP-1-producing L-cells reside in the gut epithelium; gut peptide interventions can have metabolic downstream effects. Tracking fasting glucose and HbA1c establishes whether metabolic dysfunction is a co-driver of GI symptoms.

The gut health biomarker guide covers the core markers for assessing microbiome balance and intestinal function in detail. Establishing these baselines before any intervention — peptide or otherwise — is what makes subsequent changes interpretable.

How to Access These Peptides Safely

None of the peptides in this article is available over the counter. Larazotide is investigational and not available through US compounding pharmacies for general clinical use. BPC-157 is not on the FDA 503A bulks list and has no legal compounding pathway as of publication. KPV is a research compound with no legal prescribing pathway.

Any discussion of these compounds with a licensed provider requires a clinical evaluation covering your full GI history, current medications, known diagnoses (IBD, celiac disease, or related conditions), and baseline lab work. A provider experienced in gut health and investigational compounds can assess whether any of these are relevant to your clinical picture — and whether any legally available options (including larazotide in trial enrollment) are appropriate.

The gut health space includes numerous unregulated products marketed with language that conflates preclinical evidence with clinical efficacy. The distinction matters: animal data showing mucosal healing does not translate directly to human dosing protocols, safety profiles, or clinical outcomes. Products sold outside licensed pharmacy channels as BPC-157 or KPV cannot be verified for purity, potency, or identity.

Understanding Your Baseline

With three compounds in this article — each targeting different GI mechanisms at different evidence levels — baseline biomarker data is what makes a provider conversation clinically grounded. The question is not "which gut peptide should I take" but "what does my inflammatory picture, liver function, and metabolic profile actually show, and which mechanism is most likely to be relevant to my presentation?" That is the question a baseline panel positions a provider to answer.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to an investigational protocol, a referral to a gastroenterologist, or a dietary and lifestyle approach, the starting point is the same: knowing where your biomarkers stand.

IMPORTANT SAFETY INFORMATION

BPC-157 is not approved by the FDA for any medical use. In April 2026, FDA removed BPC-157 from its interim Category 2 list without placing it on Category 1; BPC-157 is not on the FDA 503A bulks list and is not eligible for 503A compounding in the United States as of publication. BPC-157 is also not on the 503B clinical need list and is not a component of any FDA-approved drug; no 503B outsourcing pathway exists. No US 503A or 503B compounding pathway is available for BPC-157. Research on BPC-157 has been limited primarily to laboratory and animal studies. Safety and efficacy for any human indication have not been established through adequate and well-controlled clinical trials. BPC-157 is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

KPV (Lys-Pro-Val) is not approved by the FDA for any medical use. In April 2026, FDA removed KPV from its interim Category 2 list without placing it on Category 1; KPV is not on the FDA 503A bulks list, is not on the 503B clinical need list, and has no legal compounding or prescribing pathway in the United States. Research on KPV has been limited primarily to in vitro cell models and murine colitis studies. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. KPV is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

Larazotide acetate is an investigational drug. It has not been approved by the FDA for any indication. Larazotide's Phase 3 celiac disease program did not meet its primary endpoint in 2022, and the sponsor did not subsequently pursue FDA approval for the celiac indication. It is not currently available through US compounding pharmacies for general clinical use. Larazotide is not prescribed or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

All injectable peptide therapies require a prescription from a licensed healthcare provider. This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide compound. Individual health history, GI diagnoses, current medications, and baseline lab values affect both eligibility and response.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.